Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs
Release Date:
Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc. Hosted on Acast. See acast.com/privacy for more information.
Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs